NCT01972373View on ClinicalTrials.gov

Visualization of Rectal Cancer During Endoscopy, Using a Fluorescent Tracer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

January 31, 2017

Conditions
Rectal Cancer
Interventions
DRUG

Bevacizumab-IRDye800CW

Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW prior to the endoscopic procedure

DEVICE

NIR fluorescence endoscopy

48-72 hours administration of Bevacizumab-IRDye800CW a flexible NIR fluorescence endoscopy will be performed via the rectum

Trial Locations (1)

9713 GZ

University Medical Centre Groningen, Groningen

All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

lead

University Medical Center Groningen

OTHER

NCT01972373 - Visualization of Rectal Cancer During Endoscopy, Using a Fluorescent Tracer | Biotech Hunter | Biotech Hunter